INEXION
The Longevity Data Company
Longevity Medicine · Multi-Source Registry · Partner-Led

The data infrastructure
layer for longevity
medicine.

Harmonizing the major public health datasets with the longitudinal cash-pay outcomes every claims-based platform is structurally blind to — through partnerships with longevity clinics, telehealth platforms, and medical societies.

For Physicians For Life Sciences For Investors
$128B+
The data-generating economy — our source pool
25K+
Patient records · Gate 2 Series A trigger (May 2027)
8
Public datasets in the spine
The Problem

Longevity medicine is generating extraordinary data.
Almost none of it is being captured.

Longevity care is delivered through thousands of independent cash-pay practices — outside hospital systems, outside insurance networks. This patient population generates zero claims data. IQVIA, Komodo, Symphony, and every legacy health-data platform are structurally blind to it. The most valuable cohort in healthcare is invisible to the systems built to study it. INEXION is the entity capturing it.

01
The Data Registry
A multi-source longitudinal health registry — de-identified, structured, outcomes-linked. The clinical-grade longevity dataset that has never existed in any licensable form.
02
Three Data Layers
8-dataset public spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare) for population baseline. Private partner contributions (telehealth platforms, longevity clinics, EHR partners) for cash-pay outcomes. Medical society partnerships (A4M, Longevity Docs) for breadth.
03
Structural Invisibility
Cash-pay longevity patients generate no claims data, so the incumbents you would expect to outspend us cannot even see this population. Money does not fix a data-access problem. Four forces then compound the lead: capital cannot buy longitudinal time, partner exclusivity and schema switching costs lock the supply side, a two-sided benchmarking flywheel strengthens with every clinic, and the first FDA-qualified biomarker owns a regulatory lane.
04
The Comp Set
Flatiron proved the exit — $1.9B to Roche (oncology data). Verana and Komodo proved the mechanism — pharma pays for registry data. IQVIA proves the revenue — $3.5B+ in analytics. INEXION is engineered for the Flatiron outcome in longevity.
How The Registry Is Built

Three data layers.
One unified schema.

INEXION integrates three data layers under a common data model: a public-data spine for population baseline, private partner contributions for the cash-pay longevity cohort, and medical society partnerships for breadth. Schema enforced at the integration layer. Scale without acquisition. Capital-light by design.

5
Public Datasets · Population Spine
NHANES, BRFSS, and HRS deployed today. MIDAS arriving. All of Us, UK Biobank, MIDUS, and CMS Medicare in pipeline. The population-level baseline against which partner-contributed cohorts are benchmarked.
25K+
Patient Records · Gate 2 Series A Trigger
By May 2027: $500K ARR + 2+ active LOIs + 25K patient records + 3+ Type-1 partners operational. Series A raise begins ($10–15M · institutional and strategic investors).
100K+
Patient Records · Scale
By 2028. 50+ partners across clinic, telehealth, and EHR networks. Multiple licensing contracts active. Registry publishable, licensable, foundation for clinical research partnerships.
Leadership

Operator-built. Clinically grounded. Ready to scale.

Ian Wendt
Ian Wendt
Founder & CEO
Ian brings three decades of biopharma commercial leadership to INEXION, with deep expertise in launch strategy, market access, and business development. Most recently Chief Commercial Officer at Jaguar Health, he founded INEXION to apply the same revenue discipline that launches blockbuster drugs to a new category: longevity data infrastructure. Co-host of The RealPharma Podcast. MBA, Dalhousie University.
Gilead SciencesBoehringer IngelheimJaguar Health
Na-Ri Oh
Na-Ri Oh, MD
Co-Founder & COO
Physician and global biopharma executive who bridges clinical medicine and commercial strategy. Practiced as an Infectious Disease physician before leading commercial and strategic planning initiatives across HIV, viral hepatitis, and liver disease at Boehringer Ingelheim and Gilead Sciences. Now leads INEXION's Department of Defense partnership as company liaison. Co-host of The RealPharma Podcast. Angel investor and LP at Black Canyon Ventures and VC Fellow at the Material Change Institute. MD, Heidelberg University.
Gilead SciencesBoehringer Ingelheim
Nirav Vira
Nirav Vira
Chief Technology Officer
25+ years building healthcare data platforms and AI-powered SaaS products. At Verana Health, built a data lake spanning 50 million patients and seven years of longitudinal EMR data. At WithMe Health as CTO, architected a multi-product ecosystem with three distinct revenue lines. At Change Healthcare, built the "Single Source of Truth" data infrastructure powering enterprise analytics. B.E., University of Mumbai.
Verana HealthChange Healthcare
Raghav Sehgal
Raghav Sehgal, PhD
Chief Scientific Officer
Forbes 30 Under 30 (Healthcare, 2025). Yale Research Faculty in biological aging and epigenomics — trained under Morgan Levine (PhenoAge co-author; SYMPHONYAge, Nature). Director, Yale Longevity Clinic. 18+ peer-reviewed publications spanning biological age clocks, epigenomics, and longevity biomarker validation.
Yale UniversityForbes
Coming Soon · INEXION Clocks
Practice software built for longevity clinics.
Biological-age analytics, protocol tracking, and longitudinal patient timelines — with registry benchmarking built in. Demo complete; first clinic deployments this summer.
Early access →
For Physicians & Clinics
Join the registry.
Contribute your de-identified patient data. Access aggregated insights, benchmarking, and research collaboration in return. Standard Data Use Agreement only.
View Details
For Life Sciences
Get on the partner list.
The longevity data registry pharma can't build internally. Data licensing, clinical trial site network, and AI/ML training datasets — early-access partner program now live.
View Details
For Federal
The analytic layer for readiness.
AI and machine-learning analytics on de-identified DoD and partner data. VA-precedented Datavant architecture, no PHI handling. A federal analytics contractor purpose-built for warfighter readiness and force health preservation.
View Details
For Investors
Request the investor brief.
We're raising a seed round with a select group of aligned investors — family offices, angels, and venture funds. Series A ($10–15M) will be led by institutional and strategic healthcare investors.
Investor Overview